Title : A phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a Pediatric Brain Tumor Consortium study.

Pub. Date : 2021 Oct 1

PMID : 33631016






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 METHODS: We present results from children with recurrent/progressive OPHGs treated on a PBTC phase 2 trial evaluating efficacy of selumetinib, (AZD6244, ARRY-142886) a MEK-1/2 inhibitor. AZD 6244 mitogen-activated protein kinase kinase 1 Homo sapiens